NASDAQ:PRVLPrevail Therapeutics Stock Price, Forecast & News

Prevail Therapeutics' stock was trading at $12.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PRVL stock has increased by 34.4% and is now trading at $16.85. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prevail Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Prevail Therapeutics.

Prevail Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Prevail Therapeutics.

Prevail Therapeutics Inc. (NASDAQ:PRVL) posted its quarterly earnings results on Thursday, May, 14th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.06. View Prevail Therapeutics' earnings history.

7 Wall Street analysts have issued 1-year price objectives for Prevail Therapeutics' stock. Their forecasts range from $15.00 to $25.00. On average, they expect Prevail Therapeutics' share price to reach $21.00 in the next year. This suggests a possible upside of 24.6% from the stock's current price. View analysts' price targets for Prevail Therapeutics.

Press coverage about PRVL stock has trended extremely negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Prevail Therapeutics earned a media sentiment score of -4.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutPrevail Therapeutics.

Prevail Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 1,220,000 shares, an increase of 8.9% from the March 31st total of 1,120,000 shares. Based on an average daily volume of 148,300 shares, the days-to-cover ratio is presently 8.2 days. Approximately 4.4% of the shares of the company are short sold. View Prevail Therapeutics' Current Options Chain.

Some companies that are related to Prevail Therapeutics include Bill.com (RVMD), Adverum Biotechnologies (ADVM), Sangamo Therapeutics (SGMO), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Twist Bioscience (TWST), I-Mab (BDTX), Mesoblast (MESO), Regenxbio (RGNX), Cortexyme (CRTX), Coherus Biosciences (CHRS), Beam Therapeutics (BEAM), Translate Bio (TBIO), NanoString Technologies (NSTG) and Passage Bio (PASG). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Prevail Therapeutics investors own include Editas Medicine (EDIT), AbbVie (ABBV), Alector (ALEC), Crispr Therapeutics (CRSP), Gossamer Bio (GOSS), Stoke Therapeutics (STOK), TG Therapeutics (TGTX), Atreca (BCEL), Gilead Sciences (GILD) and Myovant Sciences (MYOV).

(PRVL) raised $126 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Prevail Therapeutics trades on the NASDAQ under the ticker symbol "PRVL."

Prevail Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include RA Capital Management L.P. (9.47%), BlackRock Inc. (3.32%), Bank of New York Mellon Corp (0.66%), State Street Corp (0.61%), Geode Capital Management LLC (0.45%) and QVT Financial LP (0.39%). View institutional ownership trends for Prevail Therapeutics.

PRVL stock was sold by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Squarepoint Ops LLC, and UBS Group AG. View insider buying and selling activity for Prevail Therapeutics.

PRVL stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., QVT Financial LP, State Street Corp, Morgan Stanley, Geode Capital Management LLC, Nuveen Asset Management LLC, Two Sigma Investments LP, and JPMorgan Chase & Co.. View insider buying and selling activity for Prevail Therapeutics.

Shares of PRVL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PRVL stock can currently be purchased for approximately $16.85.

Prevail Therapeutics has a market capitalization of $576.27 million. The company earns $-63,190,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis. Prevail Therapeutics employs 33 workers across the globe.

The official website for Prevail Therapeutics is www.prevailtherapeutics.com.

Prevail Therapeutics' mailing address is 430 East 29th Street Suite 1520, New York NY, 10016. The company can be reached via phone at 917-336-9310 or via email at [email protected]